Paxil Suit Shows Off-Label Prosecutions By States Can Be "More Dangerous" Than Federal Cases
This article was originally published in The Pink Sheet Daily
Executive Summary
Former federal prosecutor Reed Stephens compares the implications of the Paxil lawsuit to those from the Neurontin case. Companies can "inoculate" themselves against federal anti-kickback cases, whereas state consumer protection cases are less predictable, Stephens says.